Edition:
United Kingdom

Sawai Pharmaceutical Co Ltd (4555.T)

4555.T on Tokyo Stock Exchange

6,180JPY
17 Nov 2017
Change (% chg)

¥50 (+0.82%)
Prev Close
¥6,130
Open
¥6,120
Day's High
¥6,200
Day's Low
¥6,070
Volume
278,100
Avg. Vol
185,119
52-wk High
¥6,700
52-wk Low
¥5,700

Chart for

About

SAWAI PHARMACEUTICAL CO., LTD. is a Japan-based pharmaceutical company. The Company is engaged in the manufacture and sale of ethical drugs and proprietary drugs. The Company primarily provides central nerve system drugs, circulatory drugs, alimentary canal drugs, vitamin drugs, blood and body fluid drugs, metabolic medicinal... (more)

Overall

Beta: 0.46
Market Cap(Mil.): ¥247,727.09
Shares Outstanding(Mil.): 38.17
Dividend: 65.00
Yield (%): 2.00

Financials

  Industry Sector
P/E (TTM): -- 31.15 16.44
EPS (TTM): -- -- --
ROI: -- 14.99 10.62
ROE: -- 16.33 14.20

REFILE-TABLE-Sawai Pharmaceutical- 6-MTH group results

(Adds company forecast. Accounting policy for forecast is IFRS) Nov 13 (Reuters)- Sawai Pharmaceutical Co Ltd CONSOLIDATED FINANCIAL HIGHLIGHTS (in billions of yen unless specified) 6 months ended 6 months ended Year to Sep 30, 2017 Sep 30, 2016 Mar 31, 2018 LATEST YEAR-AGO LATEST RESULTS RESULTS FORECAST Sales 70.76 65.42

13 Nov 2017

BRIEF-Sawai Pharmaceutical to sell 20 pct stake in SAWAI AMERICA for $211 mln

* Says it plans to sell 20 percent stake in a wholly owned U.S.-based unit SAWAI AMERICA INC to Sumitomo Corporation of Americas, a wholly owned unit of SUMITOMO CORPORATION, for $211 million (23.2 billion yen)

13 Nov 2017

BRIEF-Upsher-Smith says parent co to manufacture migraine medication in Japan With AstraZeneca

* Upsher-Smith Laboratories says co's parent Sawai Pharmaceutical entered agreement with AstraZeneca to manufacture & market migraine medication in Japan​

30 Oct 2017

REFILE-TABLE-Sawai Pharmaceutical-Q1 group results

(Adds company forecast. Accounting policy for forecast is IFRS) Aug 14 (Reuters)- Sawai Pharmaceutical Co Ltd CONSOLIDATED FINANCIAL HIGHLIGHTS (in billions of yen unless specified) 3 months ended 3 months ended Year to Jun 30, 2017 Jun 30, 2016 Mar 31, 2018 LATEST YEAR-AGO LATEST RESULTS RESULTS FORECAST Sales 33.65 32.95 

14 Aug 2017

BRIEF- Sawai Pharmaceutical completes acquisition of Upsher-Smith Laboratories for $1.05 bln

* Says it acquired U.S.-based company Upsher-Smith Laboratories, LLC, which is engaged in manufacture and sales of generic drug, for $1.05 billion (about 116.5 billion yen), on May 31 (U.S. local time)

01 Jun 2017

Earnings vs. Estimates